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data about antimicrobial resistance 
wherever it is occurring. Both the UN 
Food and Agriculture Organization 
and the World Organisation for Animal 
Health are joining WHO to ensure the 
integration of data from the human 
and animal health sector and from the 
agriculture and food industries.2 WHO 
will invite countries to join the GLASS 
via an open call at their website. 
Effective implementation requires 
the needs of low-income and middle-
income countries to be addressed, 
their workforces to be trained to do 
surveillance, and improvement of their 
access to the microbiology laboratory. 
Achievement of these targets needs 
time but is key to adequately deal 
with the disease burden of health- 
care-associated infections and 
antimicrobial resistance. The beneﬁ ts 
of addressing antimicrobial resistance 
are global. Therefore, developed 
nations must help developing 
countries to equip themselves for 
such an initiative and to identify steps 
that might be relevant for diverse 
conditions. An important relevant 
initiative was taken at a recent 
Asian Pacific Economic Coalition 
and Global Health Security Agenda 
meeting, which outlined several 
key components for establishing 
robust infection prevention and 
control infrastructure.7 One of them—
promotion of hand hygiene using 
alcohol-based handrub at the point 
of patient care—has received much 
attention in both developed and 
developing countries because of the 
major infection prevention eﬀ ect of 
this simple technique that can be cost-
effectively launched in low-income 
and middle-income countries.8  For 
greater reach and possibility of earlier 
implementation, the initiatives taken 
by governments can be combined with 
public–private partnerships.
Additionally, new resistance in 
a pathogenic bacterium with no 
treatment options should be notiﬁ able 
under International Health Regulations 
to relevant authorities and control 
measures must be implemented 
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A global health partnership between 
countries is now an international 
priority. Infectious disease transcends 
borders, cultures, and demographics, 
leaving long-term devastating eﬀ ects. 
Antimicrobial resistance is now 
widely recognised as a major threat 
to global health security. Infections 
caused by resistant bacteria can be 
endemic, or can occur as an epidemic. 
Bacteria that have evolved to become 
resistant to existing drugs can lead to 
life-threatening infections with few 
or no treatment options. They can 
spread rapidly around health-care 
facilities, move across borders, and 
jump continents. Although warnings 
about antimicrobial resistance were 
ﬁ rst raised more than 50 years ago, 
the problem has escalated into a 
global crisis. WHO and the Global 
Health Security Agenda (GHSA) have 
prioritised combating antibiotic 
resistant bacteria on a global level.1,2 A 
recent important development is the 
endorsement of a global action plan 
for antimicrobial resistance at the 
69th World Health Assembly in May, 
2015.2 Global surveillance is one of the 
core pillars of this action plan because 
without such surveillance we cannot 
even begin to understand the extent 
of the problem, its geographical reach, 
or the effect on our populations, 
health-care systems, and economies. 
The starting point is to address the 
huge gap in surveillance capabilities 
identified in 2014 by the WHO’s 
first global report on surveillance of 
antimicrobial resistance.3 To address 
this gap, WHO’s action plan is being 
implemented in phases from early 
2016 onwards, gathering information 
from an initial set of countries with 
institutional capacities to implement 
the programme, assessing that 
information while enabling other 
countries to collect and analyse 
information, and making progress 
with other phases of data analysis 
and developing policy responses at 
the global, regional, and national 
level. Full implementation will need 
a few years of collaborative effort. 
To achieve the best possible results, 
we need to understand the different 
conditions prevailing across developed 
and developing economies. The 2014 
WHO global report showed that many 
countries do not have the capacity 
or systems to undertake surveillance 
of antimicrobial resistance, with 
data deﬁ ciencies in large parts of the 
world, existing systems remaining 
largely uncoordinated, and data being 
shared infrequently. Although some 
regional systems and global disease-
speciﬁ c systems exist, no overall global 
system for surveillance of antimicrobial 
resistance exists to bridge the gaps, pool 
data from all sources, and do analyses 
to better understand the problem and 
drive effective solutions.4 The efforts 
at WHO also need to be supplemented 
by other initiatives that are already 
addressing some of these issues.
In December, 2014, in Stockholm, 
Sweden, WHO, along with its member 
states and partner organisations, 
proposed an agreed set of standards 
for surveillance of antimicrobial 
resistance.5 These standards list the 
priority bacteria and diseases for 
surveillance; explain the metrics to 
be used to ascertain the incidence 
of resistance; and advise how the 
data should be collected, reported, 
and analysed. Recently the proposed 
standards were published as a 
manual: the Global Antimicrobial 
Resistance Surveillance System 
(GLASS) for all countries to collaborate 
in the surveillance of antimicrobial 
resistance.6 GLASS should be 
coordinated with a national action 
plan on antimicrobial resistance prior 
to participation. The programme 
requires active participation and input 
of partners around the world—in 
local health-care facilities, national 
laboratories, ministries, and regional 
networks. It will even reach out 
beyond the health sector to capture 
For the GLASS website see 
http://www.who.int/
drugresistance/surveillance/en/
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without delay. 9 This approach will work 
only if the new systems developing 
across the world, both regionally and 
globally, are connected and share a 
common approach to build synergies 
and partnerships for robust and 
eﬀ ective systems. 
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